1. Medtech Insight
  2. >>Device Area
  3. >>Neurology

Neuro Panel Takeaways: Detailed Responses On Aneurysm Devices From US FDA Advisors

Point-by-point clinical trial recommendations from US FDA's Neurological Devices Advisory Panel at a recent meeting on intracranial aneurysm devices.

FDA Advisory Committee Feature image

US FDA's Neurological Devices Advisory Panel convened March 1 in Gaithersburg, Md., to discuss and give recommendations to the agency on what should be required of sponsors when conducting clinical trials for intracranial aneurysm devices and making product submissions. Also see "Brain Trust Advises US FDA On Aneurysm Device Trials" - Medtech Insight, 2 March, 2018.

At the end of the meeting, Christopher Loftus, chief medical officer in the Division of Neurological and Physical Medicine Devices...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurology

More from Device Area

Fallouh Healthcare Receives Grant Funding From Innovate UK

 
• By Natasha Barrow

Fallouh Healthcare has received £305,050 in grant funding from Innovate UK as part of the European Union’s Eureka Eurostars program. The company aims to detect cardiac tamponade, a condition that affects patients after heart surgery. Currently, there is no way to accurately diagnose the condition.

Newborn Screening Tests Among FDA Classifications

 
• By Elizabeth Orr

The US FDA has announced classifications for five device types, including four diagnostics as well as a hand cream to protect healthcare workers exposed to radiation. Two of the products are newborn screening tests.

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 
• By Natasha Barrow

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.